Dr. Hudson on the Rise of Liquid Biopsies in Lung Cancer

Video

Kathryn E. Hudson, MD, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.

Kathryn E. Hudson, MD, hematologist and oncologist, director, Survivorship for Texas Oncology, Texas Oncology, discusses the rise of liquid biopsies as a tool for molecular testing in lung cancer.

Liquid biopsies are emerging as a more common option used by oncologists to test for biomarkers, though their acceptance is limited by lack of data, explains Hudson. Additionally, there are no large panel liquid biopsy tests currently approved by the FDA.

Currently, tumor tissue is the most standard and well-accepted way to perform molecular testing; however, liquid biopsies are available to get information should a tissue biopsy not be possible, concludes Hudson.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,